For patients

Can I participate?

You can participate in this European project when you are 16 years of age* or older at the day of signing the informed consent for biopsy taking. You have to have a confirmed diagnosis of CF and a rare genetic profile (see below: Is my genetic profile rare?). You also need to be able to make one visit to one of the participating hospitals to collect rectal biopsies for making your unique organoids. Also, if you will be selected for a clinical trial you will need to visit this hospital for probably 6-8 times.

*18 years or older in some countries because of national laws

Is my genetic profile rare?

Only patients with rare genotypes can participate in the HIT-CF Europe project. You cannot participate if you have :

  • one of the following mutations: F508del, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, R117H, A455E, 3849+10kbC>T, or
  • a combination of any two of the following mutations: G542X, 1717-1G>A, 621+1G>T, 3120+1G>A, 1898+1G->A, CFTRdele2,3 and 2183AA->G

What are additional inclusion and exclusion criteria?

Inclusion criteria -> you can participate if:

  • You have a confirmed diagnosis of CF by your doctor. CF must have been diagnosed by the following:
    • The new-born screen or one or more CF symptoms or sibling(s) with CF 
    • Your sweat test result (SSC) is higher than 60 mmol/L 

Exclusion criteria -> you cannot participate in this project if:

  • You have an additional disease (comorbidity) that increases the risk of administering a drug candidate if you would be selected for a clinical trial. For example, you have severe liver disease. During your first visit for the project the investigator will decide whether you have a comorbidity that might put you at risk for this study.
  • You have had a lung transplantation

What is the timeline for this project?

You can apply for participating in this project from March 2018 onwards in one of the participating CF-centers. From April 2018 on biopsies will be taken from 500 people with CF .

The subsequent laboratory tests of drug candidates on organoids will be finished by June 2020.

Based on the responses in organoids, 75 patients will be selected for clinical trials. The clinical trials with the drug candidates will start at the second half of 2020.

How can I participate?

The HIT-CF Europe project will be carried out in specific CF-Centers of the Clinical Trial Network (CTN) of the European CF Society (ECFS) (see map).

A list of the participating Centers and contact details is shown below. Other centers are still in a preparatory phase and will become active HIT-CF participating Centers in the coming months

Hospitals currently participating in HIT-CF Europe

  • UZ Leuven (Belgium) – or 016 34 38 61
  • UZ Brussel (Belgium) – or 02 477 57 65
  • Motol University Hospital Prague (Czech Republic) – / or 702013011
  • Rigshospitalet Copenhagen (Denmark)
  • Hadassah Medical Center Jerusalem (Israel) – or 0507 874801
  • Schneider Children’s Petah Tikva (Israel) – or 972 3 9253654
  • Azieda Ospedaliera Universitaria Integrata Verona (Italy)
  • Bambino Gesu Hospital Rome (Italy)
  • Sapienza University Hospital Rome (Italy)
  • Genoa CF Center (Italy)
  • UMC Utrecht (Netherlands) – or 088 75 561 37
  • Institute of Mother and Child Warsaw (Poland)
  • Hospital Vall d’Hebron Barcelona (Spain) – or 093 4893197
  • Stockholm CF center (Sweden)
  • Göteborg CF center (Sweden)
  • Royal Brompton Hospital London (United Kingdom)
  • Birmingham CF Center (United Kingdom)

Hospitals in a preparatory phase – not recruiting at this moment

  • Bordeaux University Hospital (France)
  • Lille CF Center (France)
  • West Paris (France)
  • France North West
  • Strasbourg CF Center (France)
  • Mucomed (France)
  • Lyon CF Center (France)
  • Turin CF Center (Italy)
  • Florence CF Center (Italy)
  • Milan CF Center (Italy)
  • Hospital de Santa Maria Lisbon (Portugal)

You can contact your physician to confirm whether you could participate. If your CF-Center is not part of the CTN, your physician can guide you towards a nearby HIT-CF Europe study site where you could participate.

  • German, Austrian and Swiss patients will be referred to The Netherlands for participation in HIT-CF
  • Norwegian and Finnish patients will be referred to Sweden for participation in HIT-CF
  • Slovak patients will be referred to the Czech Republic for participation in HIT-CF

For more information, you can also contact HIT-CF Europe directly via

Additional important information

If you sign an additional consent, your mini-intestines will be stored in a biobank for future research.

I want to participate


Share this page:

Contact information

HIT-CF Europe
Joseph Borlélaan 12
1160  Brussels